190 related articles for article (PubMed ID: 36847968)
1. Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.
Tharwat EK; Abdelaty AO; Abdelrahman AI; Elsaeed H; Elgohary A; El-Feky AS; Ebrahim YM; Sakraan A; Ismail HA; Khadrawy YA; Aboul Ezz HS; Noor NA; Fahmy HM; Mohammed HS; Mohammed FF; Radwan NM; Ahmed NA
Metab Brain Dis; 2023 Jun; 38(5):1513-1529. PubMed ID: 36847968
[TBL] [Abstract][Full Text] [Related]
2. Cerebrolysin potentiates the antidepressant effect of lithium in a rat model of depression.
Abdelaty AO; Tharwat EK; Abdelrahman AI; Elgohary A; Elsaeed H; El-Feky AS; Ebrahim YM; Habib A; Abd El Latif H; Khadrawy YA; Aboul Ezz HS; Noor NA; Fahmy HM; Mohammed FF; Radwan NM; Ahmed NA
J Psychiatr Res; 2024 Apr; 172():171-180. PubMed ID: 38394763
[TBL] [Abstract][Full Text] [Related]
3. A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease.
Noor NA; Mohammed HS; Mourad IM; Khadrawy YA; Aboul Ezz HS
Life Sci; 2016 Jun; 155():174-9. PubMed ID: 27210889
[TBL] [Abstract][Full Text] [Related]
4. Transcranial photobiomodulation ameliorates midbrain and striatum neurochemical impairments and behavioral deficits in reserpine-induced parkinsonism in rats.
Mohammed HS; Hosny EN; Sawie HG; Khadrawy YA
Photochem Photobiol Sci; 2023 Dec; 22(12):2891-2904. PubMed ID: 37917308
[TBL] [Abstract][Full Text] [Related]
5. Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence.
El-Marasy SA; El Awdan SA; Hassan A; Ahmed-Farid OA; Ogaly HA
Chem Biol Interact; 2021 Jan; 334():109329. PubMed ID: 33279466
[TBL] [Abstract][Full Text] [Related]
6. Testosterone propionate improves motor alterations and dopaminergic damage in the reserpine-induced progressive model of Parkinson's disease.
Bispo JMM; Melo JEC; Gois AM; Medeiros KAAL; Silva RS; Leal PC; Franco HS; Souza MF; Lins LCRF; Ribeiro AM; Silva RH; Santos JR
Brain Res Bull; 2022 Sep; 187():162-168. PubMed ID: 35781030
[TBL] [Abstract][Full Text] [Related]
7. Effects of graphene oxide nanoparticles administration against reserpine-induced neurobehavioral damage and oxidative stress in an animal model of Parkinson's disease.
Oukhrib M; Tamegart L; Assafi A; Hejji L; Azzouz A; Villarejo LP; Haida M; Mohamed C; Gamrani H
Food Chem Toxicol; 2023 Aug; 178():113904. PubMed ID: 37356558
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective and Therapeutic Effect of Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone.
Khadrawy YA; Salem AM; El-Shamy KA; Ahmed EK; Fadl NN; Hosny EN
J Diet Suppl; 2017 Sep; 14(5):553-572. PubMed ID: 28301304
[TBL] [Abstract][Full Text] [Related]
9. Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine.
Lins LCRF; Souza MF; Bispo JMM; Gois AM; Melo TCS; Andrade RAS; Quintans-Junior LJ; Ribeiro AM; Silva RH; Santos JR; Marchioro M
Brain Res Bull; 2018 May; 139():9-15. PubMed ID: 29378222
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of EGb761® and low-dose whole-body γ-irradiation in a rat model of Parkinson's disease.
El-Ghazaly MA; Sadik NA; Rashed ER; Abd-El-Fattah AA
Toxicol Ind Health; 2015 Dec; 31(12):1128-43. PubMed ID: 23696346
[TBL] [Abstract][Full Text] [Related]
11. Effects of obesity on neuroinflammatory and neurochemical parameters in an animal model of reserpine-induced Parkinson's disease.
Cavalheiro EKFF; da Silva LE; Oliveira MP; Silva MG; Damiani AP; Ribeiro CB; Magenis ML; Cucker L; Michels M; Joaquim L; Machado RS; Vilela TC; Bitencourt RM; Andrade VM; Dal-Pizzol F; Petronilho F; Tuon T; Rezin GT
Behav Brain Res; 2022 Sep; 434():114019. PubMed ID: 35872330
[TBL] [Abstract][Full Text] [Related]
12. Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson's disease.
Leão AHFF; Meurer YSR; Freitas TA; Medeiros AM; Abílio VC; Izídio GS; Conceição IM; Ribeiro AM; Silva RH
Behav Brain Res; 2021 Jul; 410():113349. PubMed ID: 33971246
[TBL] [Abstract][Full Text] [Related]
13. Effects of gold nanoparticles administration through behavioral and oxidative parameters in animal model of Parkinson's disease.
da Silva Córneo E; de Bem Silveira G; Scussel R; Correa MEAB; da Silva Abel J; Luiz GP; Feuser PE; Silveira PCL; Machado-de-Ávila RA
Colloids Surf B Biointerfaces; 2020 Dec; 196():111302. PubMed ID: 32777662
[TBL] [Abstract][Full Text] [Related]
14. Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism.
Melo JEC; Santos TFO; Santos RS; Franco HS; Monteiro MCN; Bispo JMM; Mendonça MS; Ribeiro AM; Silva RH; Gois AM; Marchioro M; Lins LCRF; Santos JR
J Chem Neuroanat; 2022 Nov; 125():102162. PubMed ID: 36115503
[TBL] [Abstract][Full Text] [Related]
15. Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.
Leão AH; Sarmento-Silva AJ; Santos JR; Ribeiro AM; Silva RH
Brain Pathol; 2015 Jul; 25(4):377-90. PubMed ID: 25726735
[TBL] [Abstract][Full Text] [Related]
16. Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression.
Leão AH; Meurer YS; da Silva AF; Medeiros AM; Campêlo CL; Abílio VC; Engelberth RC; Cavalcante JS; Izídio GS; Ribeiro AM; Silva RH
Front Aging Neurosci; 2017; 9():78. PubMed ID: 28396635
[TBL] [Abstract][Full Text] [Related]
17. Cannabis exacerbates depressive symptoms in rat model induced by reserpine.
Khadrawy YA; Sawie HG; Abdel-Salam OME; Hosny EN
Behav Brain Res; 2017 May; 324():41-50. PubMed ID: 28212939
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of 5-HT1b/1d agonist on Parkinson's disease by modulating glutamate and reducing deposition of α-synuclein.
Tripathi AS; Fatima N; Tripathi P; Tripathi R; Alka ; Zaki MEA; Mohapatra L; Yasir M; Maurya RK
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23627. PubMed ID: 38229316
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the neuroprotective effect of green synthesized iron oxide nanoparticles capped with curcumin against a rat model of Parkinson's disease.
Khadrawy YA; Hosny EN; Eldein Mohamed HS
Iran J Basic Med Sci; 2024; 27(1):81-89. PubMed ID: 38164480
[TBL] [Abstract][Full Text] [Related]
20. Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism.
Leal PC; Bispo JMM; Lins LCRF; Souza MF; Gois AM; Moore C; Marchioro M; Ribeiro AM; Silva RH; Meshul CK; Santos JR
Brain Res Bull; 2019 Mar; 146():213-223. PubMed ID: 30641120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
